Capital

A 1.4 Billion Valuation On Someone Else's Licence

The EBRD led a 20.1 million euro round into Ominimo at a 1.4 billion valuation on 27 July. The premium it writes sits on Signal Iduna and Zurich balance sheets.

CapitalBy Servola Tech Desk2026-07-285 min read

AI-assisted, edited by humans. | Editor-in-Chief: Leon Soliman | Editorial standards

A 1.4 Billion Valuation On Someone Else's Licence

Key takeaways

Ominimo was valued at 1.4 billion euros on 27 July while administering roughly 307 million euros of annual motor premium that it does not underwrite, and the first announced use of the new money is to buy an insurance licence of its own.
The round was 20.1 million euros, about 1.4 percent of the company. A raise that small against a valuation that large is a price-setting event rather than a funding event, so read the use of funds instead of the headline number.
Zurich is the risk carrier in three of the four live markets through DA Direkt, the distribution partner, and a minority shareholder from the Series A. One counterparty holding all three roles is a concentration worth naming before it is worth worrying about.
Apply the same test to your own accounts. If a share of your gross volume moves under a permission somebody else holds, that revenue is real but the enterprise value built on it is contingent, and no standard metric shows the difference.

What the EBRD actually bought

On 27 July the venture arm of the European Bank for Reconstruction and Development led a 20.1 million euro Series B into a Budapest motor insurer that did not exist three years ago. The valuation attached to the cheque was 1.4 billion euros, about 1.6 billion dollars, making Ominimo the first company founded by Serbians to reach unicorn status. Dusan Komar, Dennis Weinbender and Laslo Horvath started it in 2024. It sells one product, motor insurance, in four countries, and it has been profitable in Hungary since launch.

Why it matters: the growth is not in dispute. Annualised gross written premium went from 26.3 million euros in 2024 to 157.8 million in 2025 and now sits near 307 million. The EBRD notes that Ominimo reached a billion-euro valuation faster than any company it has backed before, a list that includes PandaDoc, DocPlanner and PicsArt. What deserves the second look is not whether the company is growing. It is what the 1.4 billion is a multiple of.

The policy is written on someone else's paper

Ominimo is a managing general agent. It prices the risk, sells the policy, owns the customer relationship and handles the claim. It does not carry the risk. The insurance sits on partner balance sheets: Signal Iduna in Hungary, and DA Direkt, part of Zurich, in Poland, the Netherlands and Sweden. This is a legitimate and widespread structure, and it is the reason a two-year-old company can be writing 307 million euros of premium at all. The capital requirements that Solvency II imposes on an insurer do not fall on an agent.

The consequence: that 307 million is a premium pool Ominimo administers, not revenue it books. Its income is commission on the pool, paid by carriers who can retune underwriting appetite, renegotiate terms, or decline to renew the arrangement. A 1.4 billion euro valuation against 307 million of gross written premium is roughly four and a half times a number that belongs, in the accounting sense, to somebody else.

One point four percent is a price, not a raise

Do the division. Taking 20.1 million against 1.4 billion works out at about 1.4 percent of the company. A profitable business that is not burning cash did not need 20 million euros to keep operating, and the company says as much: the capital is for the next phase of growth rather than day-to-day operations. What a round this small at a valuation this large actually delivers is a mark. It puts a defensible number on the equity, set by a development bank rather than by a growth fund with an exit clock running.

Read the use of funds instead. Top of the list is securing an insurance licence of its own. Everything after it, Belgium and Romania this summer, then Spain, Italy, France and a United States launch in 2027, leans on that permission. A licence turns Ominimo from a company that rents underwriting capacity into one that carries it, and that is a different business with different capital rules, a different regulator, and a different reason to be worth 1.4 billion.

Zurich sits on both sides of the table

Zurich is Ominimo's distribution partner, the risk carrier through DA Direkt in three of its four live markets, and a minority shareholder from the Series A. That concentration is worth naming plainly, because the licence plan resolves it in one direction only. If Ominimo becomes an insurer in its own right, it begins competing for the same motor premium as the balance sheet that currently makes its business possible, while that same group holds equity in the challenger.

Yes, but: this is not a scandal, and nothing in the announcement suggests either side is unhappy. Incumbent insurers routinely take stakes in the agents distributing for them, precisely to keep an option on the outcome. The point for a reader is narrower than the governance question. When one counterparty is at once your supplier, your channel and your shareholder, your enterprise value is entangled with a relationship you do not fully control, and the round that prices you highest is the moment that entanglement is easiest to overlook.

The question to ask about your own numbers

Very few readers run a motor insurer. A great many run something that sits on top of a permission granted by another company: a marketplace listing, a banking-as-a-service licence, a payment institution's rails, a cloud marketplace, an app store. The pattern is identical. Revenue earned through the arrangement is real and countable. Enterprise value built on it is contingent, and the contingency appears in none of the metrics normally put in front of an investor.

The bottom line: separate the two lines in your own reporting before somebody else does it for you. Write down what share of gross volume moves under a permission you do not hold, name the counterparty that could withdraw it, and state what the business is worth on the day after it does. Ominimo's founders have evidently run that calculation, which is why the first thing they are buying with EBRD money is a licence rather than growth.

Frequently asked questions

Is Ominimo an insurance company?

Not in the regulatory sense, not yet. It operates as a managing general agent, which means it handles pricing, distribution, customer relationships and claims while the insurance risk stays on a licensed carrier's balance sheet. In Hungary that carrier is Signal Iduna; in Poland, the Netherlands and Sweden it is DA Direkt, part of Zurich. Securing its own insurance licence is the first stated use of the Series B, which would move it from agent to risk carrier and bring it under the full Solvency II capital regime.

Why would a profitable company raise only 20.1 million euros?

Because the money is not the point. At a 1.4 billion euro valuation, 20.1 million is roughly 1.4 percent of the equity, and a business that is already profitable and generating cash does not need that sum to keep trading. A round structured this way primarily establishes a price, and doing it with a development bank rather than a growth fund sets that price without importing an exit timetable. The signal to read is the use of funds, which is dominated by the licence application and the market expansion that depends on it.

What actually changes if Ominimo gets its own insurance licence?

Three things at once. It would begin holding regulatory capital against the policies it writes, under Solvency II rules that currently apply to its partners rather than to it. It would keep the underwriting margin instead of a commission, which changes what the 307 million euros of gross written premium is worth to it. And it would stop depending on carriers whose appetite can change, which is the dependency the current valuation quietly assumes away. The trade is a heavier balance sheet in exchange for owning the economics.

The number that made the headlines on 27 July was 1.4 billion euros. The number that decides whether it holds is the one nobody printed: the share of that premium Ominimo still controls on the day a partner carrier decides to write the business itself. Buying a licence is the founders' own answer to that question, and it is the right one.

OminimoEBRDZurichManaging general agentSolvency IIInsurtechPlatform dependency

A Leaked Call Paused a 480 Billion Yuan Round

DeepSeek suspended its second funding round on 25 July after its founder's remarks leaked. What he said matters more to a European buyer than the pause does.

3 min read

Capital

A Fourth DRAM Supplier Just Raised 8.6 Billion

CXMT listed in Shanghai on 27 July and rose 470 percent. The debut number is not the one that changes a European memory budget. The 57.92 billion yuan raise is.

5 min read

Law & Regulation

The EA Buyout Now Hinges on Brussels

The largest take-private in history has cleared EA shareholders and US antitrust. The last real gate is the EU - and not classic merger review, but the Foreign Subsidies Regulation, facing its first blockbuster test.